Literature DB >> 8411457

Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg.

K G Naber1, F Sörgel, M Kinzig, D M Weigel.   

Abstract

To evaluate an effective dose for the treatment of bacterial prostatitis the concentrations of ciprofloxacin were measured in prostatic fluid, ejaculate and the cell-free seminal fluid of 15 healthy volunteers who received an oral dose of 750 mg. ciprofloxacin while in a fasting state. Venous blood samples were taken in all subjects at 1, 2, 3 and 4 hours. In 6 subjects blood samples were also taken after 8 and 12 hours. Urine was collected in all subjects during 0 to 4 hours and in the 6 subjects also during 4 to 8 hours and 8 to 12 hours. Prostatic fluid could be obtained in 10 subjects by prostatic massage 4 hours after drug intake. So as not to contaminate the urethra with ciprofloxacin the subjects were not allowed to void until 4 hours after drug intake. Iopamidol (3.162 gm.), a renal contrast agent, was administered intravenously concomitantly with oral ciprofloxacin intake. After 8 hours iohexol (3.235 gm.) was administered intravenously. These agents were measured in prostatic fluid, ejaculate and seminal fluid to assess the contamination of those fluids by urine. All drug measurements were done by high pressure liquid chromatography. The median plasma concentrations of ciprofloxacin were 2.1 mg./l. at 1 hour (maximum concentration), 0.9 mg./l. at 4 hours and 0.2 mg./l. at 12 hours. The median concentration in prostatic fluid was 0.23 mg./l. with a fluid-to-plasma concentration ratio of 0.23. The median concentration in the ejaculate (seminal fluid) after 4 hours was 7.4 mg./l. (6.6 mg./l.) and after 12 hours it was 2.0 mg./l. (1.9 mg./l.) with corresponding ejaculate (seminal fluid)-to-plasma concentration ratios of 8.4 (7.7) and 8.0 (6.6), respectively. Thus, ciprofloxacin is concentrated several-fold in ejaculate and seminal fluid but not in prostatic fluid. According to the results the concentrations of ciprofloxacin in prostatic fluid exceed the minimal inhibitory concentration-90% for Enterobacteriaceae but not for Pseudomonas, enterococci and staphylococci, whereas the concentrations in ejaculate and seminal fluid are sufficiently elevated to include the total spectrum of sensitive strains causing bacterial prostatis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8411457     DOI: 10.1016/s0022-5347(17)35877-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Fluoroquinolone Antimicrobial Agents in the Treatment of Prostatitis and Recurrent Urinary Tract Infections in Men.

Authors:  F M E Wagenlehner; K G Naber
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

Review 2.  Prostatitis: the role of antibiotic treatment.

Authors:  F M E Wagenlehner; K G Naber
Journal:  World J Urol       Date:  2003-04-10       Impact factor: 4.226

3.  Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers.

Authors:  C K Naber; M Steghafner; M Kinzig-Schippers; C Sauber; F Sörgel; H J Stahlberg; K G Naber
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

4.  Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers.

Authors:  C K Naber; M Hammer; M Kinzig-Schippers; C Sauber; F Sörgel; E A Bygate; A J Fairless; K Machka; K G Naber
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 5.  Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.

Authors:  Andrew Chou; Elwyn Welch; Andrew Hunter; Barbara W Trautner
Journal:  Drugs       Date:  2022-03-14       Impact factor: 11.431

6.  A new method to estimate quantitatively seminal vesicle and prostate gland contributions to ejaculate.

Authors:  Themba T Ndovi; Teresa Parsons; Leena Choi; Brian Caffo; Charles Rohde; Craig W Hendrix
Journal:  Br J Clin Pharmacol       Date:  2006-10-31       Impact factor: 4.335

7.  Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.

Authors:  Florian M E Wagenlehner; Stephan Wydra; Hajime Onda; Martina Kinzig-Schippers; Fritz Sörgel; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil.

Authors:  Leonidas A Bourikas; George Kolios; Vassilis Valatas; George Notas; Ioannis Drygiannakis; Iordanis Pelagiadis; Pinelopi Manousou; Stefanos Klironomos; Ioannis A Mouzas; Elias Kouroumalis
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

Review 9.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

Review 10.  Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men.

Authors:  F M E Wagenlehner; K G Naber
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.